By reMind Staff —
Marking a victory for psychedelics advocates, the Drug Enforcement Agency announced Friday it was withdrawing its proposal to place five more tryptamines in schedule I of the Controlled Substances Act.
The reversal follows intense pushback from psychedelics researchers, legal experts and the general public over the agency’s proposal in January to ban five tryptamines — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT. The agency had argued the compounds have “a high potential for abuse and no currently accepted medical use,” a claim psychedelics experts strongly disputed.
The DEA also canceled a public hearing about the proposal, which was slated for Aug. 22.
“Upon further consideration, DEA has determined that it is appropriate to submit a new request … for an updated scientific and medical evaluation and scheduling recommendation for these substances. Accordingly, DEA is withdrawing the proposed rule and … canceling the public hearing,” the agency said in a statement.
Attorneys Graham Pechenik of Calyx Law and Matt Zorn of Yetter Coleman led the challenge against the proposal, supported by a host of psychedelics firms and advocates, including Tactogen, Mindstate Design Labs, Panacea Plant Medicine, Hamilton Morris, and Jason Wallach.
“This is a remarkable and unprecedented outcome,” Pechenick said.
While the announcement gave psychedelics supporters cause to celebrate, the DEA was clear that it “may issue a new proposed rule in the future regarding these substances if warranted.”